OncoSil Clinical Trial Update April 2018
Australian medical device company OncoSil Medical has been actively progressing their global clinical trial, PanCO, which is testing the efficacy of the Company’s OncoSilTM device in patients with advanced pancreatic cancer that cannot be treated with surgery.
The OncoSilTM device is a unique brachytherapy device, implanted through an endoscopic ultrasound (EUS), which works by emitting a dose of beta radiation into a patient’s cancerous pancreatic tumour(s). The device is used in combination with chemotherapy.
To date, the trial has recruited 40 patients internationally, and 29 of these patients have been implanted with the device. The trial has been widely supported in Australia, taking place at major research centres including Monash Medical Centre, The Austin Hospital in Melbourne, St Vincent’s , Royal North Shore and Westmead Hospitals in Sydney, Corrimal Cancer Care Centre, Wollongong and Royal Adelaide Hospital.
Excitingly, the Company recently announced that two implanted patients have undergone surgical resection – meaning the OncoSilTM device, in combination with chemotherapy, has taken these patient’s tumours from an inoperable to an operable state.
This is a remarkable milestone for the treatment landscape of pancreatic cancer, both in Australia and around the world and we look forward to seeing further results from the company.
Last week, OncoSil’s study was featured on WIN News in the Illawarra Region of NSW. The network aired a story featuring a local Wollongong patient currently enrolled in the trial. To watch, click here.
If you, or someone you know, would like to receive more information about the PanCO clinical trial – please contact Pancare on email@example.com or call 1300 881 698